DA
UTHR icon

Duality Advisers’s United Therapeutics UTHR Stock Holding History

Duality Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,522
Closed -$3.11M – 511
2024
Q1 		$3.11M Sell
13,522
-2,120
-14% -$478K 0.31% 104
2023
Q4 		$3.44M Buy
15,642
+5,622
+56% +$1.3M 0.36% 74
2023
Q3 		$2.26M Sell
10,020
-864
-8% -$199K 0.27% 131
2023
Q2 		$2.4M Buy
10,884
+2,412
+28% +$534K 0.3% 121
2023
Q1 		$1.9M Buy
+8,472
New +$2.09M 0.21% 174
2022
Q2 		– Sell
-10,458
Closed -$1.88M – 872
2022
Q1 		$1.88M Buy
10,458
+8,842
+547% +$1.68M 0.2% 173
2021
Q4 		$349K Sell
1,616
-16,122
-91% -$3.16M 0.04% 431
2021
Q3 		$3.27M Buy
17,738
+15,770
+801% +$3.11M 0.25% 158
2021
Q2 		$353K Sell
1,968
-498
-20% -$94.8K 0.03% 465
2021
Q1 		$412K Sell
2,466
-4,125
-63% -$688K 0.04% 465
2020
Q4 		$1M Sell
6,591
-5,599
-46% -$735K 0.07% 344
2020
Q3 		$1.23M Buy
+12,190
New +$1.34M 0.08% 322

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Duality Advisers's UTHR Position: Q2 2024 in Review

Duality Advisers sold out of United Therapeutics (UTHR) in Q2 2024, closing a stake of 13,522 shares — an estimated $3.11M sold.

Duality Advisers first reported a position in UTHR in Q3 2020 and held it in 12 quarters. The position peaked at $3.44M in Q4 2023. 566 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

  • Duality Advisers reported no remaining United Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Duality Advisers sold 13,522 United Therapeutics shares in Q2 2024, an estimated $3.11M.
  • Duality Advisers first reported a position in United Therapeutics in Q3 2020 and held it in 12 quarters.
  • Duality Advisers's United Therapeutics position peaked at $3.44M in Q4 2023.
  • 566 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.